drugset / Trial / NCT00150462
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
Timeline
- Start
- 2005-09
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 1.2 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 2.4 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 4 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 6 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 8.4 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 11 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 27 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |